Targeting GSK-3: a promising approach for cancer therapy?
Targeting GSK-3: a promising approach for cancer therapy? Read More »
Search Results for: c
Investors
INVESTOR OVERVIEW Corporate profile Actuate is a clinical-stage biopharmaceutical company dedicated to developing [cutting-edge] therapies for cancers with high unmet needs. The company’s product candidate, elraglusib is a small molecule GSK-3 inhibitor designed to restore balance in the NF-κB pathway, effectively reducing inflammation, chemoresistance, and tumor progression. Elraglusib injection is being developed as a potential
FAQs
FAQs Corporate FAQs Where is Actuate headquartered? Our corporate headquarters is in Fort Worth, Texas How is Actuate stock traded? Our shares are traded on NASDAQ Global Market under the stock symbol ACTU When was Actuate incorporated? Actuate was incorporated on January 16, 2015 When did Actuate go public? Actuate went public on August 13,
MEDIA
PUBLICATIONS PARTNERING As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations. < COLLABORATE WITH US >
PIPELINE
PIPELINE CLINICAL TRIALS If you or a loved one are living with cancer, and you’re interested in learning about our clinical trials we currently have open, click below to learn more. < SEE OUR TRIALS >
TIMELINE
TIMELINE 2024 December 17, 2024 Positive Interim Phase 2 Data of Elraglusib in pancreatic cancer August 14, 2024 Initial Public Offering August 1, 2024 FDA Orphan Drug Designation for Elraglusib February 9, 2024 The Last Patient’s First Dose of Elraglusib in pancreatic cancer January 2024 Completion of Enrollment in Phase 2 clinical study in